智通财经APP获悉，周三，美股减肥药概念股走强，截至发稿，硕迪生物(GPCR.US)涨超5%，诺和诺德 (NVO.US)涨超3.5%，罗氏(RHHBY.US)涨超3%，礼来(LLY.US)微涨。消息面上，此前硕迪生物公布其 每日一次、口服小分子GLP-1受体激动剂aleniglipron在ACCESS临床项目中取得积极顶线结果。 ...

Core Viewpoint - The pharmaceutical industry is currently overly focused on GLP-1 weight loss drugs, leading to irrational stock prices for companies not in this spotlight [1][12]. Group 1: Eli Lilly (LLY) - Eli Lilly is the leader in the GLP-1 drug market with products like Mounjaro and Zepbound, significantly boosting its performance [3]. - The company's price-to-earnings (P/E) ratio is nearly 50, slightly below its five-year average of 53, indicating a high valuation [5]. - Over 50% of Eli Lilly's revenue comes from its GLP-1 drugs, raising concerns about the sustainability of its market dominance [6]. Group 2: Merck (MRK) - Merck focuses on cardiovascular conditions, cancer, and infectious diseases, positioning itself outside the GLP-1 competition [7]. - The current P/E ratio for Merck is 13, significantly lower than its five-year average of 21, suggesting a more attractive valuation [8]. - Merck offers a dividend yield of 3.4%, appealing to dividend investors [8][10]. Group 3: Bristol Myers Squibb (BMY) - Bristol Myers Squibb also operates in areas like cardiovascular, cancer, and immune disorders, not competing directly with Eli Lilly [7]. - The P/E ratio for Bristol Myers Squibb is 17.5, which is still lower than Eli Lilly's, despite recent losses affecting its five-year average [8]. - The company has a dividend yield of 4.9%, which is attractive for conservative investors [10]. Group 4: Industry Insights - The pharmaceutical sector is characterized by the patent cliff phenomenon, where drugmakers must continually seek new drugs to maintain profitability [6]. - Merck and Bristol Myers Squibb are established companies with a history of long-term success, indicating they remain viable investment options despite current market trends [11].

Core Insights - The article aims to compare Novo Nordisk (NVO) with its main competitor Eli Lilly (LLY) and five other large-cap pharmaceutical companies to assess whether NVO is undervalued [1] - The author emphasizes the importance of identifying reasonably priced companies with strong long-term growth prospects and uncovering small- and mid-cap companies with potential for exponential growth through fundamental analysis [1] Company Analysis - Novo Nordisk is positioned against Eli Lilly and five other major pharmaceutical companies to evaluate its market valuation [1] - The analysis focuses on the financials, business fundamentals, and valuations of these companies to determine investment opportunities [1] Investment Philosophy - The article reflects a belief that educated individuals can outperform the market by understanding basic accounting and financial principles [1]

智通财经APP获悉，法国生物科技公司Abivax(ABVX.US)周三在巴黎股市和美股盘前走高，此次有报道 指出，此番股价异动源于市场对减肥药巨头礼来(LLY.US)可能发起收购要约的猜测。 事实上，这家总部位于巴黎的企业早已不是首次卷入收购传闻。金融情报机构Betaville此前于9月和11 月两度发布关于Abivax可能被收购的"未经核实"市场猜测，均曾推动其美国存托凭证(ADR)价格上涨。 回溯今年7月，Abivax曾公布重磅利好：其每日一次口服的obefazimod，在两项治疗溃疡性结肠炎的Ⅲ 期临床试验中均达到主要终点，消息一出，公司股价随即迎来暴涨。 作为一家临床阶段生物科技企业，Abivax的核心在研产品obefazimod主要用于治疗溃疡性结肠炎等炎症 性疾病。截至发稿，该公司股价在巴黎股市上涨逾10%，对应市值攀升至约80亿欧元(折合93亿美元)， 较今年年初5亿欧元的估值实现大幅跃升。美股盘前，该股涨超9%。 "此番股价波动的核心驱动因素，是市场对于潜在收购交易的猜测，"Stifel分析师Damien Choplain表 示。 礼来对此回应称："我们不对业务发展活动发表评论。" ...

Core Insights - The gene therapy (CGT) sector is experiencing a significant decline in venture capital investment, with deals dropping by approximately 61% from 2021 to 2025, and CGT-specific deals decreasing by 66% in the same timeframe [1][2] Industry Trends - Half of the CGT venture capital activity is concentrated in Series B funding, indicating a shift from platform validation to clinical studies, reflecting a broader trend in the pharmaceutical industry towards less risky targets like obesity drugs and antibody-drug conjugates (ADCs) [2] - The average value of CGT venture capital deals is currently around $60 million in 2025, which is notably lower compared to other modalities, highlighting a decrease in deal frequency and value [3] Market Dynamics - The peak activity for venture capital in the CGT sector occurred in 2021, but commercial challenges have led some companies to withdraw from the space despite the presence of approved CGT therapies in major markets like the US and Europe [4] - Companies such as Galapagos and Takeda have recently exited the cell therapy sector, indicating a shift in focus towards small molecules, biologics, and ADCs [5] Acquisition Strategies - There is ongoing interest from biopharma companies in CGT technologies, primarily through acquisitions rather than in-house development, with a focus on platforms and scalable manufacturing systems [6] - Eli Lilly has been notably active in the CGT space, investing $475 million in a licensing deal for ophthalmology gene therapy and acquiring Adverum Biotechnologies for over $260 million, along with a $1.3 billion investment in Rznomics for RNA-based gene therapies [6]

Core Viewpoint - Shares of French biotech company Abivax increased by 20% due to market speculation regarding a potential bid from U.S. pharmaceutical giant Eli Lilly [1] Company Summary - Abivax is a French biotech firm experiencing a significant rise in share price, attributed to rumors of interest from Eli Lilly [1] Industry Summary - The news highlights the potential for mergers and acquisitions within the biotech sector, particularly involving established pharmaceutical companies like Eli Lilly [1]

本文来自彭博终端，终端用户可运行NSN T6EOMEKIJH8G 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 全球市场版图日新月异，彭博行业研究（Bloomberg Intelligence）为您的企业战略助力。在 制药与生物技术领域，无论是全球行业资讯与热点，还是制药管线里程碑及催化剂事件、财务 预测…… BI涵盖广泛且深度的关键信息，旨在为您的决策提供可靠且具有竞争力的洞见支撑。 扫描二维码 立即订阅 彭博生物制药双周报 本期主题： 诺和诺德、礼来因特朗普肥胖症协议面临20亿至30亿美元销售损失 （彭博行业研究）——根据我们的情景预测，由于与白宫达成协议，礼来、诺和诺德的GLP- 1类肥胖症药物2 0 2 6年在美国市场的合计销售额将减少2 0亿- 3 0亿美元，降至2 6 4亿美元，较 市场普遍预期低6%。该协议新增1 , 0 0 0万名符合资格的联邦医疗保险(Me d i c a r e )患者，并将 GLP- 1药物价格下调2 5%- 3 5%；若目标人群渗透率从此前的4 . 5%升至6%，销量增长将部分 抵消降价影响。 覆盖范围扩大将新增1,000万Medicare患者 美国国家健康 ...

Group 1 - Eli Lilly announced a $6 billion investment to build a manufacturing facility in Huntsville, Alabama, aimed at increasing production capacity for its experimental oral weight loss drug and other medications [1] - This facility marks the third investment in a series of new U.S. facilities, following a previous announcement in February regarding a $27 billion investment to build four domestic manufacturing plants, adding to the $23 billion already invested since 2020 [1] - The Alabama facility is expected to begin construction in 2026 and be completed by 2032, enhancing supply chain resilience and ensuring reliable access to medications for U.S. patients [1] Group 2 - The new plant will create 450 jobs in the local area, including positions for engineers, scientists, operations staff, and laboratory technicians, along with 3,000 construction jobs [2] - Eli Lilly has recently lowered the price of its weight loss drug Zepbound, with the lowest dose now costing $299 per month, a reduction of about $50, while the second-highest dose will be priced at $399, down approximately $20 [2] - Eli Lilly, Pfizer, and Johnson & Johnson have secured a place in China's first innovative drug catalog, opening new market channels and enhancing sales prospects for expensive advanced therapies [2]

Group 1: Federal Reserve and Economic Policy - The Federal Reserve is facing internal divisions regarding interest rate decisions, with 10 out of 19 FOMC members opposing rate cuts, while the White House is advocating for significant easing [3] - There is a high probability of a 25 basis point rate cut in the upcoming meeting, with current estimates showing an 87.6% chance of a cut [3] - The strategy of "cutting rates first and then setting limits" may be adopted by Powell to align with market expectations while raising future easing thresholds [3] Group 2: Technology and Semiconductor Industry - The U.S. government has allowed NVIDIA to export H200 AI chips to "approved customers" in China, with a 25% revenue share taken by the government [4] - China is planning to restrict access to H200 chips to promote technological independence and support domestic AI chip development [4] - The strategic shift towards self-reliance in technology is seen as irreversible despite U.S. efforts to increase revenue through exports [4] Group 3: Corporate Developments - Eli Lilly announced a $6 billion investment to build a factory in Huntsville, Alabama, focusing on the production of the upcoming oral weight-loss drug orforglipron and other medications [10] - The factory is expected to create 450 permanent jobs and 3,000 construction jobs, with operations slated to begin in 2026 and completion by 2032 [10] - The drug orforglipron has received priority review from the FDA, with a market application expected by the end of 2025 [10] Group 4: Corporate Restructuring - Alibaba has established a new C-end business group called Qianwen, integrating its previous smart information and smart interconnect divisions [13] - The new group aims to create a super app that encompasses shopping, travel, and office services, while expanding into various devices such as glasses, PCs, and cars [13] - The management has positioned this initiative as a critical battle for the future in the AI era, focusing on providing users with AI capabilities across multiple scenarios [13]

Core Viewpoint - Eli Lilly, a major American pharmaceutical company, announced an investment of over $6 billion to build an active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, aimed at expanding domestic production and strengthening the drug supply chain [1][2]. Group 1: Investment and Production Plans - The new facility will be the third plant that Eli Lilly plans to invest in within the United States [1][2]. - The plant will produce small molecule synthesis and peptide drugs, including the company's first oral GLP-1 weight loss drug, orforglipron, which is expected to receive U.S. approval in early 2024 [1][2]. Group 2: Construction Timeline and Job Creation - Construction of the Alabama facility is expected to begin in 2026 and be completed by 2032 [3]. - The facility is projected to create 450 jobs in the region, including positions for engineers, scientists, operators, and laboratory technicians, as well as 3,000 construction jobs [3].